Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“appears essential for T cell-driven antitumor immunity (Hildner et al., 2008)”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
In the citing paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hildner et al., 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Self-citationJung, S., Unutmaz, D., Wong, P., Sano, G.-I., De los Santos, K., Sparwasser, T., Wu, S., Vuthoori, S., Ko, K., Zavala, F., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00365-5 · Cited by 1,773
Barnden, M. J., Allison, J., Heath, W. R., & Carbone, F. R. (1998) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.1998.00709.x · Cited by 1,489
Differential Antigen Processing by Dendritic Cell Subsets in Vivo
Dudziak, D., Kamphorst, A. O., Heidkamp, G. F., Buchholz, V. R., Trumpfheller, C., Yamazaki, S., Cheong, C., Liu, K., Lee, H.-W., Park, C. G., et al. (2007) · Science · doi:10.1126/science.1136080 · Cited by 1,455
Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo
den Haan, J. M. M., Lehar, S. M., & Bevan, M. J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.12.1685 · Cited by 1,328
Steady-state and inflammatory dendritic-cell development
Shortman, K., & Naik, S. H. (2007) · Nature Reviews Immunology · doi:10.1038/nri1996 · Cited by 1,190
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Bevan, M. J. (1976) · The Journal of experimental medicine · doi:10.1084/jem.143.5.1283 · Cited by 956
Toll-like receptor 3 promotes cross-priming to virus-infected cells
Schulz, O., Diebold, S. S., Chen, M., Näslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y.-T., Flavell, R. A., Liljeström, P., & Reis e Sousa, C. (2005) · Nature · doi:10.1038/nature03326 · Cited by 921
A critical function for type I interferons in cancer immunoediting
Dunn, G. P., Bruce, A. T., Sheehan, K. C. F., Shankaran, V., Uppaluri, R., Bui, J. D., Diamond, M. S., Koebel, C. M., Arthur, C., White, J. M., et al. (2005) · Nature Immunology · doi:10.1038/ni1213 · Cited by 605
Cited by
Items 801–900 of 1,008
Role and therapeutic value of dendritic cells in central nervous system autoimmunity
Quintana, F. J., Yeste, A., & Mascanfroni, I. D. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.125 · Cited by 56
Complementary diversification of dendritic cells and innate lymphoid cells
Briseño, C. G., Murphy, T. L., & MURPHY, K. M. M. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.04.006 · Cited by 54
Kurche, J. S., Haluszczak, C., McWilliams, J. A., Sanchez, P. J., & Kedl, R. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102550 · Cited by 47
Hochheiser, K., Klein, M., Gottschalk, C., Hoß, F., Scheu, S., Coch, C., Hartmann, G., & Kurts, C. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501958 · Cited by 55
“Development of these DCs under homeostatic conditions requires the transcription factor Batf3, and Batf3deficient mice have been used to unravel the role of CD8a DCs in immune responses (9).”
BackgroundArimura, K., Takagi, H., Uto, T., Fukaya, T., Nakamura, T., Choijookhuu, N., Hishikawa, Y., Yamashita, Y., & Sato, K. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.96 · Cited by 53
Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages
Kanemaru, H., Yamane, F., Fukushima, K., Matsuki, T., Kawasaki, T., Ebina, I., Kuniyoshi, K., Tanaka, H., Maruyama, K., Maeda, K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1708598114 · Cited by 50
“Batf3 is essential for the development of CD8 classical DCs and related CD103 DCs (14, 15).”
BackgroundIn situ vaccination with defined factors overcomes T cell exhaustion in distant tumors
Khalil, D. N., Suek, N., Campesato, L. F., Budhu, S., Redmond, D., Samstein, R. M., Krishna, C., Panageas, K. S., Capanu, M., Houghton, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128562 · Cited by 50
Cueto, F. J., del Fresno, C., Brandi, P., Combes, A. J., Hernández-García, E., Sánchez-Paulete, A. R., Enamorado, M., Bromley, C. P., Gómez, M. J., Conde‐Garrosa, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002054 · Cited by 50
Kremenovic, M., Chan, A. A., Feng, B., Bäriswyl, L., Robatel, S., Gruber, T., Tang, L., Lee, D. J., & Schenk, M. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004133 · Cited by 49
Moreo, E., Jarit-Cabanillas, A., Robles‐Vera, I., Uranga, S., Guerrero, C., Gómez, A. B., Mata-Martínez, P., Minute, L., Araujo‐Voces, M., Felgueres, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41768-8 · Cited by 48
Long, H., Lichtnekert, J., Andrassy, J., Schraml, B. U., Romagnani, P., & Anders, H.-J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194988 · Cited by 46
Self-citationAntibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3−/− mice
Caminschi, I., Vremec, D., Ahmet, F., Lahoud, M. H., Villadangos, J. A., MURPHY, K. M. M., Heath, W. R., & Shortman, K. (2011) · Molecular Immunology · doi:10.1016/j.molimm.2011.11.008 · Cited by 46
CD103+ Dendritic Cells Producing Interleukin-12 in Anticancer Immunosurveillance
Zitvogel, L., & Kroemer, G. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.008 · Cited by 53
“Tumor growth was accelerated in Irf8 / Cancer Cell 26, N mice but not in CD11c-Cre;Irf4fl/fl mice, in line with the possibility that only CD103+ DC2 (but not CD11b+ DC1) participate in immunosurveillance as previously suggested (Hildner et al., 2008).”
BackgroundTargeting Batf2 for infectious diseases and cancer
Guler, R., Roy, S., Suzuki, H., & Brombacher, F. (2015) · Oncotarget · doi:10.18632/oncotarget.5576 · Cited by 51
“For example, Batf3 is critical for CD8α+ dendritic cell development [8] and both Batf and Batf2 can compensate for Batf3 in this process (Figure 1A-1C).”
BackgroundTGF-β inhibitor Smad7 regulates dendritic cell-induced autoimmunity
Lukas, D., Yogev, N., Kel, J. M., Regen, T., Mufazalov, I. A., Tang, Y., Wanke, F., Reizis, B., Müller, W., Kurschus, F. C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615065114 · Cited by 48
Liu, K. (2016) · Encyclopedia of Cell Biology · doi:10.1016/b978-0-12-394447-4.30111-0 · Cited by 46
“Batf3dependent CD8aþ DCs in mice and their functional equivalent BDCA3þ DCs in humans excel in cross-presenting exogenous antigens (Hildner et al., 2008; Poulin et al., 2010; Schreibelt et al., 2012).”
Zhou, Y., Ye, T., Ye, C., Wan, C., Yuan, S., Liu, Y., Li, T., Jiang, F., Lovell, J. F., Jin, H., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.07.019 · Cited by 45
“Dendritic cells (DCs), as the most important APCs, are critical for cross-presenting tumor antigens and providing co-stimulatory signals to T cells [8,9].”
BackgroundSui, Q., Chen, Z., Hu, Z., Huang, Y., Liang, J., Bi, G., Bian, Y., Zhao, M., Zhan, C., Lin, Z., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03372-0 · Cited by 57
“In other words, it plays important role in cross-presentation in tumor rejection and deletion of the transcription factor Batf3 ablated development of CD8alpha + dendritic cells [28].”
BackgroundJu, H., Park, K. W., Kim, I., Cave, J. W., & Cho, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02552-5 · Cited by 54
Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis
Guillerey, C., Chow, M. T., Miles, K. M., Olver, S. D., Sceneay, J., Takeda, K., Möller, A., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1027468 · Cited by 50
Batf3 and Id2 Have a Synergistic Effect on Irf8-Directed Classical CD8α+ Dendritic Cell Development
Jaiswal, H., Kaushik, M., Sougrat, R., Gupta, M., Dey, A., Verma, R., Ozato, K., & Tailor, P. B. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203541 · Cited by 51
“three transcription factors that are essential for the development of CD8a DCs (18, 23, 27, 53, 55, 56).”
BackgroundGainey, M., Rivenbark, J. G., Cho, H., Yang, L.-P., & Yokoyama, W. (2012) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.1217111109 · Cited by 48
“As is consistent with this hypothesis, our results show that WT- and Δ12Δ203 CPXVspecific CD8+ T-cell priming is reduced by up to fivefold in Batf3deficient mice that lack CD8α+ and CD103+ cross-presenting DCs (16, 17).”
BackgroundResultInfluentialThe development and function of dendritic cell populations and their regulation by miRNAs
Zhou, H., & Wu, L. (2017) · Protein & Cell · doi:10.1007/s13238-017-0398-2 · Cited by 50
“They are developmentally related to the CD8α+ cDCs that reside in secondary lymphoid tissues (Crozat et al., 2011; Hildner et al., 2008).”
BackgroundImproving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity
Ishihara, J., Ishihara, A., Potin, L., Hosseinchi, P., Fukunaga, K., Damo, M., Gajewski, T. F., Swartz, M. A., & Hubbell, J. A. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0091 · Cited by 45
Nakawesi, J., This, S., Hütter, J., Boucard-Jourdin, M., Barateau, V., Muleta, K. G., Gooday, L. J., Thomsen, K., López, A. G., Ulmert, I., et al. (2020) · Mucosal Immunology · doi:10.1038/s41385-020-0276-8 · Cited by 47
Neutrophils and their role in the aetiopathogenesis of type 1 and type 2 diabetes
Giovenzana, A., Carnovale, D., Phillips, B. E., Petrelli, A., & Giannoukakis, N. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3483 · Cited by 47
Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy
Zhang, S., Chopin, M., & Nutt, S. L. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.10.004 · Cited by 47
The Japanese Encephalitis Antigenic Complex Viruses: From Structure to Immunity
Khare, B., & Kuhn, R. J. (2022) · Viruses · doi:10.3390/v14102213 · Cited by 44
Immunogenomic cancer evolution: A framework to understand cancer immunosuppression
Kumagai, S., Momoi, Y., & Nishikawa, H. (2025) · Science Immunology · doi:10.1126/sciimmunol.abo5570 · Cited by 53
Human dendritic cells — stars in the skin
Klechevsky, E. (2013) · European Journal of Immunology · doi:10.1002/eji.201343790 · Cited by 44
Milo, I., Sapoznikov, A., Kalchenko, V., Tal, O., Krauthgamer, R., van Rooijen, N., Dudziak, D., Jung, S., & Shakhar, G. (2013) · Blood · doi:10.1182/blood-2012-01-401265 · Cited by 40
Luckey, U., Schmidt, T., Pfender, N., Romer, M., Lorenz, N., Martin, S. F., Bopp, T., Schmitt, E., Nikolaev, A., Yogev, N., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.022 · Cited by 46
Cross-presentation of IgG-containing immune complexes
Baker, K., Räth, T., Lencer, W. I., Fiebiger, E., & Blumberg, R. S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1100-8 · Cited by 51
Parikh, B. A., Piersma, S. J., Pak-Wittel, M. A., Yang, L., Schreiber, R. D., & Yokoyama, W. M. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005323 · Cited by 46
“However, here we indirectly addressed the role of IL-15 priming of NK cells by DCs by utilizing Batf3-deficient mice [43] that fail to develop CD8α DC subsets.”
BackgroundEvers, B. D. G., Engel, D. R., Böhner, A. M. C., Tittel, A. P., Krause, T. A., Heuser-Loy, C., Garbi, N., Kastenmüller, W., Mack, M., Tiegs, G., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015080873 · Cited by 44
Azuma, M., Takeda, Y., Nakajima, H., Sugiyama, H., Ebihara, T., Oshiumi, H., Matsumoto, M., & Seya, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1188244 · Cited by 47
“Batf3 is minimally expressed in the common DC precursors,(33) while its expression is maximal in terminally differentiated CD8aC DC in the spleen and their equivalent cells in other tissues.(29,31) Since CD8aC DC are largely diminished in spleen in Batf3¡/¡”
BackgroundToll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production
Takaki, H., Kure, S., Oshiumi, H., Sakoda, Y., Suzuki, T., Ainai, A., Hasegawa, H., Matsumoto, M., & Seya, T. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.48 · Cited by 44
Human Tumor-Infiltrating Dendritic Cells: From In Situ Visualization to High-Dimensional Analyses
Hubert, M., Gobbini, É., Bendriss‐Vermare, N., Caux, C., & Valladeau‐Guilemond, J. (2019) · Cancers · doi:10.3390/cancers11081082 · Cited by 50
“Batf3−/− mice, a model of cDC1 deficiency, allows to demonstrate their crucial involvement in the initiation of CTL responses leading to tumor rejection [32,35,66].”
BackgroundInterplay between dendritic cells and cancer cells
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.07.008 · Cited by 44
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Aznar, M. A., Molina, C., Teijeira, A., Rodriguez, I., Azpilikueta, A., Garasa, S., Sanchez‐Paulete, A. R., Cordeiro, L., Etxeberria, I., Alvarez, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910375 · Cited by 44
“…et al, 2018) to be used in conjunction with intratumoral 17D. Immune events underlying intratumoral 17D therapeutic effects CD8-mediated antitumor responses are completely dependent on conventional type I dendritic cells (cDC1) (Hildner et al, 2008; Murphy et al, 2016; Sanchez-Paulete et al, 2017).”
MethodMicrobiota: Host Interactions in Mucosal Homeostasis and Systemic Autoimmunity
Longman, R. S., Yang, Y., Diehl, G. E., Kim, S. V., & Littman, D. R. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.020081 · Cited by 44
Álvarez, M., Molina, C., de Andrea, C. E., Fernández-Sendin, M., Villalba-Esparza, M., González-Gomariz, J., Ochoa, M. C., Teijeira, Á., Glez‐Vaz, J., Aranda, F., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002953 · Cited by 47
“C57BL/6 Batf3tm1K-mm/J (basic leucine zipper ATF-like transcription factor 3 (BATF3) knockout (KO)) 25 or wild type (WT) counterparts were kindly provided by Dr Kenneth M Murphy (Washington University, St. Louis, Missouri, USA) and bred at the Center for Applied Medical Research (CIMA) animal…”
Dysregulated haemostasis in thrombo-inflammatory disease
Klavina, P. A., León, G., Curtis, A. M., & Preston, R. J. S. (2022) · Clinical Science · doi:10.1042/cs20220208 · Cited by 55
Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses
Castaño, D., Bettini, E., Kumar, B., Chudnovskiy, A., Siv, A., Protti, G., Nakandakari-Higa, S., Ceglia, S., Luna, N. D., Chiu, J. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.023 · Cited by 50
Wylie, B., Seppanen, E. J., Xiao, K., Zemek, R. M., Zanker, D. J., Prato, S., Foley, B. A., Hart, P. H., Kroczek, R. A., Chen, W., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1019198 · Cited by 43
“This is demonstrated in mice lacking key transcription factors responsible for the development of cross-presenting DCs, such as ID2, IRF8, and Batf3 animals, which exhibit a severe deficit in the ability to elicit immune responses dependent on cross-presentation.(14,24) Recently, it has been suggested that a more appr…”
BackgroundInfluentialAntigen cross-presentation: extending recent laboratory findings to therapeutic intervention
Flinsenberg, T. W. H., Compeer, E. B., Boelens, J. J., & Boes, M. L. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04411.x · Cited by 56
Pathogen sensors and chemokine receptors in dendritic cell subsets
Kaisho, T. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.10.043 · Cited by 46
Shimoda, M., Tomimaru, Y., Charpentier, K. P., Safran, H. P., Carlson, R. I., & Wands, J. R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.016 · Cited by 42
“The CD8a+ DC subset has potent cross-presentation capabilities necessary for the induction of antitumor immunity [20]; the four cytokine cocktail increased the proportion of this subset in the DC Shimoda et al.”
BackgroundClassical dendritic cells as a unique immune cell lineage
Reizis, B. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20121038 · Cited by 43
“…characterize the function of cDCs. Previous analysis of Batf3-deficient mice showed the importance of CD8+/CD103+ cDCs for the T cell–mediated control of the intracellular protozoan parasite Toxoplasma gondii and rejection of immunogenic sarcomas (Hildner et al., 2008; Mashayekhi et al., 2011).”
BackgroundThe multifaceted role of the renal mononuclear phagocyte system
Viehmann, S. F., Böhner, A. M. C., Kurts, C., & Brähler, S. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.009 · Cited by 48
Napolitano, A., van der Veen, A. G., Bunyan, M., Borg, A., Frith, D., Howell, S. A., Kjær, S., Beling, A., Snijders, A. P., Knobeloch, K., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701322 · Cited by 46
Richter, L., Landsverk, O. J. B., Atlasy, N., Bujko, A., Yaqub, S., Horneland, R., Øyen, O. M., Aandahl, E. M., Lundin, K. E. A., Stunnenberg, H. G., et al. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0060-1 · Cited by 46
Lau, C. M., Tiniakou, I., Perez, O. A., Kirkling, M. E., Yap, G. S., Hock, H. R., & Reizis, B. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20172323 · Cited by 48
León, B., & Lund, F. E. (2019) · Immunological Reviews · doi:10.1111/imr.12758 · Cited by 49
Thioesterase PPT1 balances viral resistance and efficient T cell crosspriming in dendritic cells
Ou, P., Wen, L., Liu, X., Huang, J., Huang, X., Su, C., Wang, L., Ni, H., Reizis, B., & Yang, C. Y. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190041 · Cited by 42
“…(cDC1s; CD8α+/ CD103α+/XCR1+/DNGR-1+/BATF3-dependent DCs) are the major cross-presenting DC subset in vivo (den Haan et al., 2000; Jung et al., 2002; Hildner et al., 2008; Sancho et al., 2009; Poulin et al., 2012; Yamazaki et al., 2013; Guilliams et al., 2014; Breton et al., 2016). cDC1…”
BackgroundResultInfluentialMao, C., Beiss, V., Ho, G. W., Fields, J. L., Steinmetz, N. F., & Fiering, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005834 · Cited by 44
Once upon a prime: DCs shape cancer immunity
Zagorulya, M., & Spranger, S. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.10.006 · Cited by 50
TNF/TNFR Superfamily Members in Costimulation of T Cell Responses—Revisited
Watts, T. H., Yeung, K. K. M., Yu, T., Lee, S., & Eshraghisamani, R. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-040557 · Cited by 51
Cohen, S. B., Smith, N. L., McDougal, C. E., Pepper, M., Shah, S. M., Yap, G. S., Acha‐Orbea, H., Jiang, A., Clausen, B. E., Rudd, B. D., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402453 · Cited by 44
Cross-Presentation of Cell-Associated Antigens by Mouse Splenic Dendritic Cell Populations
Thacker, R. I., & Janssen, E. M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00041 · Cited by 49
Targeting Conventional Dendritic Cells to Fine-Tune Antibody Responses
Tesfaye, D. Y., Gudjonsson, A., Bogen, B., & Fossum, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01529 · Cited by 46
“Differentiation into cDC1s is dependent on the transcription factors IRF8 (6) and Id2 (7), and to a lesser extent BATF3 (8, 9), while cDC2 differentiation is dependent on IRF4 (10, 11).”
BackgroundMUC13 promotes the development of colitis-associated colorectal tumors via β-catenin activity
Sheng, Y., Wong, K. Y., Seim, I., Wang, R., He, Y., Wu, A., Patrick, M., Lourie, R., Schreiber, V., Giri, R., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0951-y · Cited by 46
Clonal multi-omics reveals Bcor as a negative regulator of emergency dendritic cell development
Tian, L., Tomei, S., Schreuder, J., Weber, T. S., Amann-Zalcenstein, D., Lin, D. S., Tran, J., Audiger, C., Chu, M., Jarratt, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.012 · Cited by 42
Dendritic Cell Engineering for Tumor Immunotherapy: from Biology to Clinical Translation
Bhargava, A., Mishra, D. K., Banerjee, S., & Mishra, P. K. (2012) · Immunotherapy · doi:10.2217/imt.12.40 · Cited by 45
Yu, X., Guo, C., Yi, H., Qian, J., Fisher, P. B., Subjeck, J. R., & Wang, X. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1740 · Cited by 45
Backer, R. A., Probst, H. C., & Clausen, B. E. (2023) · European Journal of Immunology · doi:10.1002/eji.202149548 · Cited by 47
Conventional type 1 dendritic cells (cDC1) in cancer immunity
Liu, P., Zhao, L., Kroemer, G., & Kepp, O. (2023) · Biology Direct · doi:10.1186/s13062-023-00430-5 · Cited by 51
Dendritic cell subsets and implications for cancer immunotherapy
Chen, M. Y., Zhang, F., Goedegebuure, S. P., & Gillanders, W. E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1393451 · Cited by 54
Selected Aspects in the Pathogenesis of Autoimmune Diseases
Nagy, G., Huszthy, P. C., Fossum, E., Konttinen, Y. T., Nakken, B., & Szodoray, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/351732 · Cited by 44
Gottschalk, C., Damuzzo, V., Gotot, J., Kroczek, R., Yagita, H., Murphy, K., Knolle, P., Ludwig-Portugall, I., & Kurts, C. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012101022 · Cited by 39
Differential Ability of Surface and Endosomal TLRs To Induce CD8 T Cell Responses In Vivo
Mandraju, R., Murray, S. E., Forman, J., & Pasare, C. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302244 · Cited by 41
Functional Impairment of Mononuclear Phagocyte System by the Human Respiratory Syncytial Virus
Böhmwald, K., Espinoza, J. A., Pulgar, R. A., Jara, E. L., & Kalergis, A. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01643 · Cited by 49
“Therefore, CD103+ cDCs work as key mediators of immunity to intracellular pathogens infecting the lungs (108, 109).”
BackgroundLai, R., Jeyanathan, M., Afkhami, S., Zganiacz, A., Hammill, J. A., Yao, Y., Kaushic, C., & Xing, Z. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701109 · Cited by 41
Cangemi, M., Montico, B., Faè, D. A., Steffan, A., & Dolcetti, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00160 · Cited by 48
“There are two major subsets of cDC: cDC1, which are HLADRCD11cCD9α and CD24 or CD103 and require the transcription factors IRF8 (146), Batf3 (147), Nfil3 (148), and Bcl6 (149) for their development.”
BackgroundIdentification of CD8α+ dendritic cells in rainbow trout (Oncorhynchus mykiss) intestine
Soleto, I., Granja, A. G., Simón, R., Morel, E., Díaz‐Rosales, P., & Tafalla, C. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.04.001 · Cited by 41
Transcriptional regulation of DC fate specification
Bosteels, C., & Scott, C. L. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.02.021 · Cited by 46
Dendritic Cells and T Cells, Partners in Atherogenesis and the Translating Road Ahead
Sun, L. J., Zhang, W., Zhao, Y., Wang, F., Liu, S., Liu, L., Zhao, L., Lu, W., Li, M., & Xu, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01456 · Cited by 46
IL-32γ potentiates tumor immunity in melanoma
Gruber, T., Kremenovic, M., Sadozai, H., Rombini, N., Bäriswyl, L., Maibach, F., Modlin, R. L., Gilliet, M. F., von Werdt, D., Hunger, R. E., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.138772 · Cited by 46
Lin, D. S. Y., Tian, L., Tomei, S., Amann‐Zalcenstein, D., Baldwin, T. M., Weber, T., Schreuder, J., Stonehouse, O. J., Rautela, J., Huntington, N. D., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00636-7 · Cited by 44
Labiano, S., Roh, V., Godfroid, C., Hiou‐Feige, A., Romero, J. F., Sum, E., Rapp, M., Boivin, G., Wyss, T., Simon, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4717 · Cited by 42
Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications
Salah, A., Wang, H., Li, Y., Ji, M., Ou, W., Qi, N., & Wu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.686544 · Cited by 50
“In Batf3−/− mice, DCs were not able to mediate rejection of highly immunogenic tumors as they lack cross-presentation potential with subsequent impairment of cytotoxic T-cell activity (Hildner et al., 2008).”
BackgroundPfirschke, C., Žilionis, R., Engblom, C., Messemaker, M., Zou, A. E., Rickelt, S., Gort-Freitas, N. A., Lin, Y., Bill, R., Siwicki, M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0326 · Cited by 48
Kidney dendritic cells in acute and chronic renal disease
Hochheiser, K., Tittel, A. P., & Kurts, C. (2010) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2010.00728.x · Cited by 43
“2009), which characterizes tissue DCs related to the CD8a DCs in lymphatic tissues (Hildner et al. 2008).”
BackgroundImmunomodulatory effect of locoregional therapy in the tumor microenvironment
Xie, L., & Meng, Z. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.017 · Cited by 42
Sharma, N., Benechet, A. P., Lefrançois, L., & Khanna, K. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500993 · Cited by 47
Gasper, D. J., Neldner, B., Plisch, E. H., Hani, R., Carrow, E. W., Imai, H., Kawaoka, Y., & Suresh, M. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1006064 · Cited by 39
Integration of Nano drug-delivery System With Cancer Immunotherapy
Nakamura, T., & Harashima, H. (2017) · Therapeutic Delivery · doi:10.4155/tde-2017-0071 · Cited by 40
Activation of human CD141+ and CD1c+ dendritic cells in vivo with combined TLR3 and TLR7/8 ligation
Pearson, F. E., Chang, K., Minoda, Y., Rojas, I. L., Haigh, O. L., Daraj, G., Tullett, K. M., & Radford, K. J. (2018) · Immunology and Cell Biology · doi:10.1111/imcb.12009 · Cited by 43
Schulz, O., Hanč, P., Böttcher, J. P., Hoogeboom, R., Diebold, S. S., Tolar, P., & Sousa, C. R. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.038 · Cited by 46
Origin and development of classical dendritic cells
Guermonprez, P., Gerber-Ferder, Y., Vaivode, K., Bourdely, P., & Helft, J. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.08.002 · Cited by 51
Qiu, Z., Khairallah, C. F., Romanov, G. A., & Sheridan, B. S. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000228 · Cited by 40
Nobs, S. P., Pohlmeier, L. M., Li, F., Kayhan, M., Becher, B., & Köpf, M. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.12.638 · Cited by 44
Therapeutic induction of tolerogenic dendritic cells via aryl hydrocarbon receptor signaling
Barroso, A., Mahler, J. V., Fonseca-Castro, P. H., & Quintana, F. J. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.003 · Cited by 42
Inflammasomes in dendritic cells: Friend or foe?
Hatscher, L., Amon, L., Heger, L., & Dudziak, D. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.04.002 · Cited by 42
Chudnovskiy, A., Castro, T. B. R., Nakandakari-Higa, S., Cui, A., Lin, C., Sade-Feldman, M., Phillips, B. K., Pae, J., Mesin, L., Bortolatto, J., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adq8843 · Cited by 50
“In general, cDC1s have higher capacity to prime CD8 + T cells, whereas migratory cDC2s are best at priming CD4 + T cells ( 9 – 11 ), although these distinctions are not absolute ( 12 ).”
The Endoplasmic Reticulum Chaperone GRP170: From Immunobiology to Cancer Therapeutics
Wang, H., Pezeshki, A. M., Yu, X., Guo, C., Subjeck, J. R., & Wang, X. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2014.00377 · Cited by 45
The transcription factor BATF modulates cytokine-mediated responses in T cells
Sopel, N., Graser, A., Mousset, S., & Finotto, S. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.03.004 · Cited by 38
Sun, T., Rojas, O. L., Li, C., Ward, L. A., Philpott, D. J., & Gommerman, J. L. (2016) · Mucosal Immunology · doi:10.1038/mi.2016.79 · Cited by 43
Draheim, M., Wlodarczyk, M. F., Crozat, K., Saliou, J., Alayi, T. D., Tomavo, S., Hassan, A., Salvioni, A., Demarta‐Gatsi, C., Sidney, J., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201708123 · Cited by 38
“In vivo, some studies showed only a limited role for cDC1 in priming CD4 T cells against a soluble antigen (Yamazaki et al, 2013) or the West Nile Virus (Hildner et al, 2008).”
BackgroundHarpur, C. M., Kato, Y., Dewi, S. T., Stankovic, S., Johnson, D. N., Bedoui, S., Whitney, P. G., Lahoud, M. H., Caminschi, I., Heath, W. R., et al. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800218 · Cited by 43
Metadata
- Authors
- Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., Schreiber, R. D., Murphy, T. L., & Murphy, K. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
- Corresponding author
- Murphy, Kenneth M.
- ORCID
- Venue
- Science
- Published
- 2008-11-14
- Volume
- 322
- Issue
- 5904
- Pages
- 1097-1100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC2756611
- OpenAlex
- W2046505430
- Cited by
- 2,081
- References
- 29
- Citations by year
- 2026: 117 · 2025: 150 · 2024: 142 · 2023: 129 · 2022: 161 · 2021: 167 · 2020: 182 · 2019: 129 · 2018: 109 · 2017: 133 · 2016: 115 · 2015: 105 · 2014: 92 · 2013: 89 · 2012: 90
- FWCI
- 23.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- Batf3, CD8α+ dendritic cells, cross-presentation, West Nile virus, tumor rejection, dendritic cell development, transcription factors, antitumor immunity
- MeSH terms
- Animals, Antibodies, Viral, Cytotoxicity, Immunologic, Dendritic Cells, Female, Fibrosarcoma, Lymphocyte Activation, Male, Mice, Inbred C57BL, Repressor Proteins, Spleen, T-Lymphocytes, Cytotoxic, West Nile Fever, West Nile virus, CD4-Positive T-Lymphocytes, CD8 Antigens, Adoptive Transfer, Cross-Priming, Basic-Leucine Zipper Transcription Factors, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.